About our research

Development of melflufen (Ygalo®)

In the late-1990s, a group of Swedish researchers based at the Karolinska Institute developed a series of cancer fighting molecules given the series name J1 to J6 that built on research into alkylating agents undertaken by Italian scientists in the 1970s. The ‘J’ recognized the contribution of one of the lead researchers, Dr Joachim Gullbo of Uppsala University, Sweden.

The molecule ‘J1’ was identified as having the most potential to deliver higher levels of cancer fighting alkylating agents to cancer cells and and is now called melflufen.

 

Pre-clinical Development

Pre-clinical research showed melflufen delivered significantly lower rates of tumour growth when compared to alkylating agents commonly used in cancer treatment. The overrepresentation of certain enzymes in cancer cells, including a family of enzymes known as peptidases, was identified early as the reason for melflufens ability to rapidly increase the presence of cancer fighting molecules in cancer cells.

Clinical Development Phases for Treatment of Late-stage Multiple Myeloma

Given the history of using alkylators in treating multiple myeloma, it was decided that the clinical development phase for melflufen would focus on patients with late-stage multiple myeloma.

A Phase 2 clinical trial was undertaken with the aim of studying the efficacy and safety of melflufen in late-stage relapsed and refractory multiple myeloma patients. This study was conducted with the support of six collaborating institutions (in the US and Europe), including Harvard University’s Dana-Farber Cancer Institute.

Results from the Phase 2 study showed that 43% of patients were progression-free of their cancer at six months and 12.5% at twelve months. The Phase 2 study also showed a median survival time of 20.7 months for patients being treated with melflufen. This contrasts with data from other studies on the current standard of care, pomalidomide, where the median survival time is 12.4 months.

The Phase 2 study results also showed that when compared to available data on standard of care, melflufen demonstrated a significantly lower incidence of those side effects that substantially reduce the day-to-day quality of life in late-stage relapsed and refractory multiple myeloma patients.

Results of the Phase 2 clinical study were presented to the US FDA in July 2016. Additional melflufen clinical data was presented at the European Hematology Association conference in Stockholm, Sweden, in June 2018.

In the course of 2015, melflufen received Orphan Drug Status in both the US and Europe.

Pivotal Phase 3 Clinical Study

Following approval of its detailed design under the US FDA’s Special Protocol Assessment in August 2016, the pivotal Phase 3 clinical study (OCEAN, OP-103) with melflufen started in June 2017 and is currently enrolling patients.

OCEAN is a global, randomized, head-to-head Phase 3 study comparing melflufen + dexamethasone versus pomalidomide + dexametasone in patients with late stage relapsed and refractory multiple myeloma. The study has been designed to have 90% certainty of achieving its targets based on historical data for both compounds.

For questions about the OCEAN study enrollement, please contact trials@oncopeptides.com.

Further Indications for melflufen

Beyond the treatment of relapsed and refractory multiple myeloma, pre-clinical studies suggest that melflufen may also be effective in a wide range of cancer indications. Oncopeptides is currently investigating the possibility of clinical studies in the high-dose setting in conjunction with bone marrow transplantation in multiple myeloma patients, also in the treatment of amyloidosis and of non-Hodgkin’s lymphoma. All these indications are examples of where alkylating agents are currently used, and where melflufen may show enhased efficacy and/or safety.